Taisho's OTC Sales Fall In Japan As Consumers Stay At Home
A drop in socializing and travelling in Japan due to the COVID-19 pandemic hit demand for Taisho's leading consumer health brands in its latest reporting period.
You may also be interested in...
Takeda is to offload its sizable Japanese OTC operation to private-equity firm Blackstone, which has committed to making the business the country's leading consumer health player.
Japan's Taisho Establishes Global OTC Footprint With $1.6bn Acquisition of Bristol-Myers Squibb's UPSA
Taisho is striking out from its Asian base to create a global OTC player through the acquisition of Bristol-Myers Squibb's UPSA. The transaction will catapult it to the number-three spot in France and give it a foothold in a slew of important emerging markets.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.